Souhaitez-vous accéder aux communiqués récents ?

– Initiative streamlines operations to focus on approval and commercial launch of OLINVO™ (oliceridine injection) and significantly reduces operating expenses –             – New Drug Application for...

CHESTERBROOK, Pa., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the 3rd Annual 2017 Healthcare Conference hosted by Ladenburg Thalmann...

– Hospital charge database study shows high prevalence of opioid-related adverse events in key surgical specialties despite use of multimodal analgesia – – Physician survey highlights the need for...

CHESTERBROOK, Pa., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the 19th Annual Global Investment Conference hosted by Rodman &...

CHESTERBROOK, Pa., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved,...

CHESTERBROOK, Pa., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved,...

– OLINVO program on track for NDA submission in September/October 2017 – – First-time-in-human study of TRV250 for acute treatment of migraine remains on track; results expected in 2H 2017 – ...

KING OF PRUSSIA, Pa., July 21, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved,...

– Company now plans to submit its New Drug Application for OLINVOTM (oliceridine injection) in September or October 2017 – – Topline results from ATHENA safety study further support potential value...

KING OF PRUSSIA, Pa., July 12, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host an Analyst Day on Thursday, July 20, 2017, in New York City. Presentations will...